Uploaded August 2024 | Updated September 2026, 1 week ago
Insilico Medicine Received IND Approval and Orphan Drug Designation from FDA for ISM6331, an AI-designed TEAD Inhibitor Targeting Solid Tumors and Mesothelioma
Insilico Medicine Received IND Approval and Orphan Drug Designation from FDA for ISM6331, an AI-designed TEAD Inhibitor Targeting Solid Tumors and Mesothelioma
![[ARDD 2024 Recap] Preserving Muscle Mass for Healthy Aging: Old Tricks and New Targets](https://i.ytimg.com/vi/tEdu00VTdK4/mqdefault.jpg "[ARDD 2024 Recap] Preserving Muscle Mass for Healthy Aging: Old Tricks and New Targets
Lykke Sylow
Dept. Biomedical Sciences
University of Copenhagen")
![[ARDD 2024 Recap] Dual-Purpose Target Discovery and Aging Research with Precious GPT Models](https://i.ytimg.com/vi/vNOfrH-aVzg/mqdefault.jpg "[ARDD 2024 Recap] Dual-Purpose Target Discovery and Aging Research with Precious GPT Models
Frank Pun
Head of Insilico Hong Kong")
